Zafgen Obesity Drug Moving to Clinical Trials Following Success in Mice, Dogs, and Women  
1/28/2011 11:18:17 AM -- The affectionate Yiddish adjective "zaftig" for voluptuous, Rubenesque women is generally positive and accepting; however, the reality of the zaftig body is one that is vulnerable to diabetes and heart disease. With a nod to zaftig in creating their company's name, the founders of Zafgen, Inc., a five-year-old, private, venture-backed biopharmaceutical firm, has recast a another company's discontinued tumor-fighting drug into the winning role of an innovative new anti-obesity drug.